X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ALEMBIC PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ALEMBIC PHARMA ABBOTT INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 40.4 24.4 165.5% View Chart
P/BV x 9.6 6.8 140.2% View Chart
Dividend Yield % 0.7 0.7 104.5%  

Financials

 ABBOTT INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
ALEMBIC PHARMA
Mar-16
ABBOTT INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110792 771.8%   
Low Rs3,996443 902.0%   
Sales per share (Unadj.) Rs1,552.2167.0 929.4%  
Earnings per share (Unadj.) Rs188.838.2 494.7%  
Cash flow per share (Unadj.) Rs196.442.0 467.8%  
Dividends per share (Unadj.) Rs55.004.00 1,375.0%  
Dividend yield (eoy) %1.10.6 168.0%  
Book value per share (Unadj.) Rs796.684.9 938.3%  
Shares outstanding (eoy) m21.25188.52 11.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.7 88.1%   
Avg P/E ratio x26.816.2 165.4%  
P/CF ratio (eoy) x25.714.7 175.0%  
Price / Book Value ratio x6.37.3 87.2%  
Dividend payout %29.110.5 277.9%   
Avg Mkt Cap Rs m107,376116,383 92.3%   
No. of employees `0003.3NA-   
Total wages/salary Rs m3,9374,214 93.4%   
Avg. sales/employee Rs Th9,929.3NM-  
Avg. wages/employee Rs Th1,185.1NM-  
Avg. net profit/employee Rs Th1,207.7NM-  
INCOME DATA
Net Sales Rs m32,98531,487 104.8%  
Other income Rs m1,17055 2,123.2%   
Total revenues Rs m34,15531,542 108.3%   
Gross profit Rs m5,24510,060 52.1%  
Depreciation Rs m162722 22.4%   
Interest Rs m3837 103.8%   
Profit before tax Rs m6,2159,356 66.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2032,160 102.0%   
Profit after tax Rs m4,0127,194 55.8%  
Gross profit margin %15.931.9 49.8%  
Effective tax rate %35.423.1 153.5%   
Net profit margin %12.222.8 53.2%  
BALANCE SHEET DATA
Current assets Rs m22,65515,066 150.4%   
Current liabilities Rs m6,6817,674 87.1%   
Net working cap to sales %48.423.5 206.3%  
Current ratio x3.42.0 172.7%  
Inventory Days Days6567 96.7%  
Debtors Days Days2941 71.8%  
Net fixed assets Rs m8358,237 10.1%   
Share capital Rs m213377 56.4%   
"Free" reserves Rs m16,71515,416 108.4%   
Net worth Rs m16,92816,005 105.8%   
Long term debt Rs m00-   
Total assets Rs m24,16224,594 98.2%  
Interest coverage x163.7255.2 64.1%   
Debt to equity ratio x00-  
Sales to assets ratio x1.41.3 106.6%   
Return on assets %16.829.4 57.0%  
Return on equity %23.744.9 52.7%  
Return on capital %36.958.7 63.0%  
Exports to sales %055.7 0.0%   
Imports to sales %010.4 0.0%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs mNA3,283 0.0%   
Fx inflow Rs m36917,811 2.1%   
Fx outflow Rs m3,8075,318 71.6%   
Net fx Rs m-3,43812,493 -27.5%   
CASH FLOW
From Operations Rs m1,5279,304 16.4%  
From Investments Rs m-2,148-3,105 69.2%  
From Financial Activity Rs m-1,024-1,959 52.3%  
Net Cashflow Rs m-1,6464,240 -38.8%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 2.9 272.4%  
FIIs % 0.1 9.1 1.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 13.9 123.0%  
Shareholders   18,270 49,328 37.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 14, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - LUPIN LTD COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS